![]() |
Name |
Corynether A
|
Molecular Formula | C15H14O6 | |
IUPAC Name* |
2-(2,4-dihydroxy-6-methylphenoxy)-4-hydroxy-6-methylbenzoic acid
|
|
SMILES |
CC1=CC(=CC(=C1C(=O)O)OC2=C(C=C(C=C2C)O)O)O
|
|
InChI |
InChI=1S/C15H14O6/c1-7-3-10(17)6-12(13(7)15(19)20)21-14-8(2)4-9(16)5-11(14)18/h3-6,16-18H,1-2H3,(H,19,20)
|
|
InChIKey |
ZXWOXXVHOUPFOK-UHFFFAOYSA-N
|
|
Synonyms |
Corynether A
|
|
CAS | NA | |
PubChem CID | 42611551 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Molecular Weight: | 290.27 | ALogp: | 2.6 |
HBD: | 4 | HBA: | 6 |
Rotatable Bonds: | 3 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 107.0 | Aromatic Rings: | 2 |
Heavy Atoms: | 21 | QED Weighted: | 0.686 |
Caco-2 Permeability: | -5.574 | MDCK Permeability: | 0.00000735 |
Pgp-inhibitor: | 0.002 | Pgp-substrate: | 0.217 |
Human Intestinal Absorption (HIA): | 0.008 | 20% Bioavailability (F20%): | 0.927 |
30% Bioavailability (F30%): | 0.052 |
Blood-Brain-Barrier Penetration (BBB): | 0.039 | Plasma Protein Binding (PPB): | 95.49% |
Volume Distribution (VD): | 0.35 | Fu: | 3.18% |
CYP1A2-inhibitor: | 0.45 | CYP1A2-substrate: | 0.211 |
CYP2C19-inhibitor: | 0.049 | CYP2C19-substrate: | 0.046 |
CYP2C9-inhibitor: | 0.399 | CYP2C9-substrate: | 0.187 |
CYP2D6-inhibitor: | 0.322 | CYP2D6-substrate: | 0.151 |
CYP3A4-inhibitor: | 0.09 | CYP3A4-substrate: | 0.097 |
Clearance (CL): | 9.666 | Half-life (T1/2): | 0.922 |
hERG Blockers: | 0.021 | Human Hepatotoxicity (H-HT): | 0.821 |
Drug-inuced Liver Injury (DILI): | 0.951 | AMES Toxicity: | 0.02 |
Rat Oral Acute Toxicity: | 0.912 | Maximum Recommended Daily Dose: | 0.875 |
Skin Sensitization: | 0.799 | Carcinogencity: | 0.045 |
Eye Corrosion: | 0.008 | Eye Irritation: | 0.917 |
Respiratory Toxicity: | 0.879 |